MediWound Ltd. (NASDAQ:MDWD) Sees Significant Growth in Short Interest

MediWound Ltd. (NASDAQ:MDWD) was the target of a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 1,284,063 shares, a growth of 20.9% from the January 15th total of 1,062,079 shares. Currently, 11.0% of the shares of the stock are short sold. Based on an average trading volume of 150,032 shares, the days-to-cover ratio is currently 8.6 days. Based on an average trading volume of 150,032 shares, the days-to-cover ratio is currently 8.6 days. Currently, 11.0% of the shares of the stock are short sold.

Institutional Investors Weigh In On MediWound

A number of large investors have recently bought and sold shares of the business. Sphera Funds Management LTD. increased its position in MediWound by 24.3% during the fourth quarter. Sphera Funds Management LTD. now owns 230,347 shares of the biopharmaceutical company’s stock worth $4,252,000 after buying an additional 45,077 shares during the last quarter. Kotler Kevin acquired a new position in shares of MediWound during the 4th quarter valued at about $6,225,000. Russell Investments Group Ltd. increased its holdings in shares of MediWound by 45.1% during the 4th quarter. Russell Investments Group Ltd. now owns 3,653 shares of the biopharmaceutical company’s stock valued at $67,000 after acquiring an additional 1,135 shares during the last quarter. Squarepoint Ops LLC bought a new position in shares of MediWound in the 4th quarter valued at approximately $297,000. Finally, Barclays PLC raised its stake in shares of MediWound by 32.5% in the 4th quarter. Barclays PLC now owns 15,276 shares of the biopharmaceutical company’s stock valued at $282,000 after acquiring an additional 3,747 shares in the last quarter. 46.83% of the stock is currently owned by institutional investors.

MediWound Trading Down 3.4%

MDWD opened at $17.12 on Thursday. The stock has a fifty day moving average price of $18.03 and a 200 day moving average price of $17.94. MediWound has a 1 year low of $14.14 and a 1 year high of $22.50. The stock has a market cap of $219.82 million, a price-to-earnings ratio of -9.01 and a beta of 0.13.

MediWound (NASDAQ:MDWD) last posted its quarterly earnings results on Thursday, November 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.57. The company had revenue of $5.43 million during the quarter, compared to the consensus estimate of $6.56 million. MediWound had a negative return on equity of 62.11% and a negative net margin of 98.43%. As a group, sell-side analysts forecast that MediWound will post -2.66 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on MDWD. HC Wainwright reissued a “buy” rating and issued a $36.00 price target (up previously from $31.00) on shares of MediWound in a research note on Friday, November 21st. Wall Street Zen raised shares of MediWound from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research report on Thursday, January 22nd. Finally, Zacks Research upgraded shares of MediWound from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 11th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $33.50.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.